Form 4: Precigen Director Sells Over 235K Shares

Jeffrey B. Kindler, a director at Precigen, Inc., sold 235,467 shares of common stock for a weighted average price of $3.6349 per share.

Summary

• Jeffrey B. Kindler, a director of Precigen, Inc. (PGEN), executed a sale of common stock.
• The transaction involved the disposition of 235,467 shares of common stock.
• The shares were sold on December 12, 2025, at a weighted average price of $3.6349 per share.
• The sale price ranged from $3.5000 to $3.7100 per share across multiple transactions.
• Following this transaction, Mr. Kindler beneficially owns 110,603 shares of Precigen common stock directly.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 4

Explanation: The sale of a significant number of shares by a director, even if pre-planned, can be perceived negatively by the market as it may suggest a lack of strong conviction or a move to diversify holdings, potentially impacting investor sentiment.

Negatives

• A director selling a significant number of shares (235,467 shares) could be interpreted by the market as a signal of reduced confidence in the company's near-term prospects, even if executed under a pre-planned trading arrangement.

Stakeholder Impact

• Shareholders may interpret the director's sale as a signal of reduced confidence in the company's future performance, potentially leading to downward pressure on the stock price.
• Investors might scrutinize the reasons behind the sale, even if it's part of a Rule 10b5-1 plan, to assess management's long-term commitment.

Key Dates

Recommendation

While the transaction was executed under a Rule 10b5-1 plan, indicating it was pre-scheduled and not necessarily a reaction to new information, a director selling a substantial block of shares (over 235,000) warrants caution. This action, reducing the director's direct beneficial ownership to 110,603 shares, could be interpreted by the market as a signal of reduced conviction or a strategic portfolio adjustment. Investors should hold and monitor for further insider activity or company-specific news that could provide more context for this significant insider sale.

Keywords

Precigen, PGEN, Insider Sale, Form 4, Jeffrey B. Kindler, Director Transaction, Stock Sale, Biotechnology